As incomplete as our understanding of the SARS-Cov2 virus behaviour is, one tool has remained a constant through all these months. Testing was vital in February; it is vital in November. But while India was woefully short of diagnostic kits then, there’s an oversupply today. 

As of 29 October, more than 300 different kits for RT-PCR RT-PCR Reverse transcription polymerase chain reaction , rapid antibody, and rapid antigen tests have been approved by the Indian Council of Medical Research (ICMR), the apex and lone agency granting permissions to kit manufacturers and distributors. 


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Sign up to our India edition to read this story instantly

To sign up, you’ll create an account that will give you access to a new free story published once a week and archive of 214+ previously published free stories from our India edition. You’ll also receive one email every morning from us introducing the day’s story.

If you’ve already signed up, just enter your email below or login using Facebook or Google.